期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺相关眼病危险因素与发病机制 被引量：4

原文传递
导出
摘要 甲状腺相关眼病（TAO）是一种器官特异性自身免疫性疾病，虽然往往伴有甲状腺功能亢进，但也可发生在原发性甲状腺功能减退、桥本甲状腺炎及甲状腺功能正常的人群。病变主要累及眼眶脂肪组织及眼外肌，大部分患者眼部表现比较轻，但严重者可致容貌受损，视力下降，甚至造成失明。近年来，随着免疫遗传学，分子生物学和免疫组织化学技术的发展，以及研究方法的更新和新技术的应用，对TAO的危险因素及发病机制有了新的认识。
作者 江利红 魏锐利
机构地区 第二军医大学长征医院眼科
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第23期1853-1855,共3页 National Medical Journal of China
基金 上海市卫生局青年科研项目基金（20114y154）
关键词 甲状腺相关眼病 发病机制 危险因素 特异性自身免疫性疾病 原发性甲状腺功能减退 免疫组织化学技术 甲状腺功能亢进 甲状腺功能正常
分类号 R77 [医药卫生—眼科] R5 [医药卫生—内科学]
  • 相关文献

参考文献23

  • 1Liu N, Li X, Liu C, et al. The association of interleukin-I alpha and interleukin-lbeta polymorphisms with the risk of Graves' disease in a case-control study and meta-analysis. Hum Immunol, 2010,71:397-401.
  • 2Khalilzadeh O, Anvari M, Esteghamati A, et al. Graves' ophthalmopathy and gene polymorphisms in interleukin-lalpha, interleukin-lbeta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Exp Ophthalmol,2009 ,37 :614-619.
  • 3Alevizaki M, Mantzou E, Cimponeriu A, et al. The Prol2A|a PPARgamma gene polymorphism : possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO). Cfin Endocrinol ( Oxf), 2009,70:464-468.
  • 4Brand OJ, Gough SC. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol, 2010,322:135-143.
  • 5Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy:resuhs of a European questionnaire study. Eur J Endocrinology/Eur Fed Endocr Soc ,2005,153:515-521.
  • 6Traisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid- associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab, 2009,94:3700-3707.
  • 7Wilmar M, Wiersinga. Graves' orbitopathy: Management of difficult cases. Indian J Endocrinol Metab, 2012, 16Suppl 2: 150-S152.
  • 8Manji N, Smith JD, Boelaert K, et al. Influences of age, gender, smoking, and family histmy on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab, 2006,91:48734880.
  • 9Stan MN, Bahn RS. Risk factors for development or deterioration of Graves' ophthahnopathy. Thyroid, 2010,20:777-783.
  • 10Huber AK, Jacobson EM, Jazdzewski K, et al. IL-23R is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/ThI7 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab, 2008,93 : 1077-1081.

二级参考文献23

  • 1Heufelder AE.Pathogenesis of ophthalmopathy in autoimmune thyroid disease[J].Rev Endocr Metab Disord,2000 1(1-2):87-95.
  • 2Weetman AP Cohen S.Gatterkc,et al.Immunohistochemical anlysis of the retrobulbar tissues in Graves'ophthalmopathy[J].Clin Eexp Immunol,1989,75:222-227.
  • 3Liblau RS,Singer SM,Mcdevitt HO.Th1 and Th2 CD4+T cell in the pathogenesis of organ-specific autoimmune diseases[J].Immunol Today,1995,16:34-38.
  • 4Aniszewski JP,Valyasevi RW,Bahn RS.Relationship between disease duration and predominant orbital T cellsubset in Graves'opthalmopathy[J].Clin Endocrinol Metab,2000,85:776-780.
  • 5Feldon SE,Park DJ,O'loughlin CW,et al Autologus T-lymphcytes stimulate proliferation of orbital fibrablasts derived from patients with Graves'opnRS.hthalmopathy[J].Invest Ophthalmol Vis Sci,2005,46(11).3913-3921.
  • 6Gianoukakis AG,Khadavi N,Smith TJ.Cytokines,Graves'disease,and thyroid-associated ophthalmopathy[J].Thyroid,2008,Sep,18(9):953-8.
  • 7罗礼清.甲状腺相关眼病[M].北京:第1版.人民卫生出版社,2005:114-115.
  • 8Wakelkam IM,Greding MN van Der Meer JW et al.Both Th1-and Th2-derived cytokines in serum are elevated in Graves'ophthalmopathy[J].Clin Exp Immunol,2000,121:453-457.
  • 9Mysliwiec J.Serum Th1 and Th2 proflie cytokine level changes in patients with Gaves' ophthalmopathy treated with corticosteroids[J].Horm Metab Res,2001,33:739-743.
  • 10Gianoukakis AG,khadavi N,Smith TJ.Cytokines,Graves'disease,and thyroid-associated ophthalmopathy[J].Thyroid,2008,18:953-958.

共引文献6

同被引文献33

  • 1Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy : reality and perspectives[ J~. Endocr Rev, 2000, 21 (2) :168-199.
  • 2Metso S, Jaatinen P, Salmi J. Graves' disease [ J ]. N Engl J Med, 2008,359( 13 ) : 1408-1409.
  • 3Mareocei C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glueoeortieoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy : results of a prospective, single-blind, randomized study[J]. J Clin Endocrinol Metab, 2001,86(8):.
  • 4Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: systematic review and meta analysis[ Jl. J Clin Endocrinol Metab, 2009,94 (8) :2708-2716.
  • 5Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO[ J]. Eur J Endocrinol, 2008, 158 (3) :273-285.
  • 6Bartalena L, Baldeschi L, Dickinson A J, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy[ J]. Thyroid, 2008,18 (3) :333-346.
  • 7Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity [ J 1. J Clin Endocrinol Metab, 2011,96 (2) :320-332.
  • 8Bahn R. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now? [ J]. Thyroid, 2012,22 (1) :1-2.
  • 9Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[ J]. J Clin Endocrinol Metab, 2004,89 ( 1 ) : 15-20.
  • 10Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves' orbitopathy : randomised placebo- controlled study[ J]. Lancet,2000,355 (9214) : 1505-1509.

引证文献4

二级引证文献50

中华医学杂志
2013年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部